Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.64 |
| ▸ | PDE5A | O76074 | 17/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | PDE2A | O00408 | 1/20 | 0.59 |
| ▸ | PDE9A | O76083 | 1/20 | 0.59 |
| ▸ | PDE4A | P27815 | 1/20 | 0.59 |
| ▸ | PDE6C | P51160 | 1/20 | 0.59 |
| ▸ | PDE1A | P54750 | 1/20 | 0.59 |
| ▸ | PDE11A | Q9HCR9 | 1/20 | 0.59 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.59 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.58 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.58 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.58 |
| ▸ | ABCC5 | O15440 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2803465 | 0.94 | KDM4E (0.63) | KDM4EPDE5AKMT2APDE2APDE9A | |
| SCHEMBL2799133 | 0.93 | KDM4E (0.60) | KDM4EPDE5AKMT2APDE2APDE9A | |
| SCHEMBL2800187 | 0.92 | KDM4E (0.65) | KDM4EPDE5AKMT2APDE2APDE9A | |
| SCHEMBL2803636 | 0.91 | KDM4E (0.69) | KDM4EPDE5AKMT2APDE2APDE9A | |
| SCHEMBL2799711 | 0.90 | KDM4E (0.62) | KDM4EPDE5AKMT2APDE2APDE9A | |
| SCHEMBL2799100 | 0.89 | PDE5A (0.67) | KDM4EPDE5AKMT2APDE2APDE9A | |
| SCHEMBL2801218 | 0.89 | PDE5A (0.60) | KDM4EPDE5AKMT2APDE2APDE9A | |
| SCHEMBL2800685 | 0.89 | PDE5A (0.63) | KDM4EPDE5AKMT2APDE2APDE9A | |
| SCHEMBL2800172 | 0.87 | KDM4E (0.73) | KDM4EPDE5AKMT2APDE2APDE9A | |
| SCHEMBL2803725 | 0.87 | PDE5A (0.71) | KDM4EPDE5AKMT2APDE2APDE9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080318949-A1 | Pyrazolopyrimidinone Derivatives, Their Preparation And Their Use | TOPHARMAN SHANGHAI CO., LTD (CN) | 2008-12-25 | — | — | US | claimed |
| EP-1961753-A1 | PYRAZOLOPYRIMIDINONE DERIVATIVES, THEIR PREPARATION AND THEIR USE | Topharman Shanghai Co., Ltd. (CN) | 2008-08-27 | — | — | EP | claimed |
| EP-2253632-A1 | Pyrazolopyramidinone derivatives, their preparation and their use | Topharman Shanghai Co., Ltd. (CN) | 2010-11-24 | — | — | EP | disclosed |
| US-20080318949-A1 | Pyrazolopyrimidinone Derivatives, Their Preparation And Their Use | TOPHARMAN SHANGHAI CO., LTD (CN) | 2008-12-25 | — | — | US | disclosed |
| EP-1961753-A1 | PYRAZOLOPYRIMIDINONE DERIVATIVES, THEIR PREPARATION AND THEIR USE | Topharman Shanghai Co., Ltd. (CN) | 2008-08-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318949-A1 | Pyrazolopyrimidinone Derivatives, Their Preparation And Their Use | PDE5A, PDE3A, PDE3B | KDM4E 776/4885PDE5A 1/4885KMT2A 3136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.